홈 > 시장보고서 > 의약품 > 신경질환

시장보고서

상품코드

1450838

간질 - 시장 규모 및 예측, 세계 및 지역별 점유율, 동향, 성장 기회 분석 보고서 : 유형별, 투여 경로별, 치료 유형별, 연령대별, 유통 채널별, 지역별

Epilepsy Market Size and Forecasts, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Route of Administration, Treatment Type, Age Group, Distribution Channel, and Geography

발행일: 2024년 02월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 230 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

간질 시장 규모는 2022년 77억 달러에서 2030년 107억 달러로 성장할 것으로 예상되며, 2022-2030년 CAGR은 4.1%로 예측됩니다.

간질은 전 세계적으로 가장 흔한 만성 신경질환 중 하나입니다. 뇌의 비정상적인 전기적 활동을 수반하는 이 질환은 가임기 미국 여성 100만 명 이상이 앓고 있습니다. 간질 유병률 증가와 간질 치료제 개발에 대한 투자 증가는 간질 시장 규모 확대에 기여하는 주목할 만한 요인입니다. 항간질약(AED)의 투여는 일반적으로 간질에 대한 1차 치료로 불립니다. 간질 환자의 약 80%는 개발도상국에 거주하고 있습니다. 소아뿐만 아니라 성인에서도 간질 치료의 대부분은 약물 요법(단독 또는 병용 요법)을 기반으로하며 수술, 신경 조절 요법, 케토제닉 다이어트와 같은 나머지 치료 접근법은 덜 자주 사용됩니다. 그러나 제품 회수가 간질 시장의 성장을 저해하고 있습니다.

연령대별 인사이트

연령대별로 간질 시장은 성인과 소아로 구분되며, 2022년 간질 시장 점유율은 성인이 더 클 것으로 예상됩니다. 또한 2022-2030년 시장에서 더 높은 CAGR을 나타낼 것으로 예상됩니다. 간질은 성인에게 발병하기 쉽다. 뇌 기능에 영향을 미치는 질환(알츠하이머병 등), 뇌종양, 뇌졸중, 두부 외상 등 성인의 뇌전증 위험 요인이 많습니다. 미국 질병예방통제센터(CDC)에 따르면, 미국에서는 18세 이상 성인 300만 명이 활동성 간질을 앓고 있습니다. 이 중 거의 100만 명이 55세 이상입니다. 인구 고령화에 따라 앞으로 더 많은 노인이 간질을 앓게 될 가능성이 있으며, 2021년에는 미국 성인의 1.1%(-286만 명)가 활동성 간질을 앓고 있는 것으로 보고되고 있습니다. 따라서 약물 요법과 치료 전략은 성인 환자를 우선시하는 경우가 많으며, 이는 이 연령대의 간질 인구 통계학적 유병률과 일치합니다.

최종 사용자 기반 인사이트

간질 시장은 유통 채널에 따라 병원 약국, 소매 약국, 기타로 분류되며, 병원 약국 부문은 2022년 간질 시장 점유율이 가장 높을 것으로 예상됩니다. 또한 소매 약국 부문은 2022-2030년 동안 시장에서 가장 높은 CAGR을 나타낼 것으로 예상됩니다. 소매 약국 매장은 처방약, 일반 의약품, 일부 빠르게 움직이는 소비재를 판매하고 관련 서비스를 제공합니다. 최신 소매 약국 체인은 디지털화, 조직화, 첨단화되어 의약품 재고를 추적하고 100% 신뢰할 수있는 제품을 판매 할 수 있습니다. 또한 소매 약국 체인은 의료비 청구 및 보험 신청을 하는 소비자에게 고부가가치 서비스를 제공합니다. 또한 과거 청구서 및 메모의 수정을 요청할 수도 있습니다. 또한 환자가 처방전을 작성하고 약사에게 상담을 받을 수 있는 편리한 위치에 있습니다.

미국 질병통제예방센터(Centers for Disease Control and Prevention), 세계보건기구(WHO), 캐나다 신경 건강 자선단체(Neurological Health Charities Canada) 등은 간질 시장 보고서 작성 시 참고한 1차 및 2차 정보 중 하나입니다.

북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 스페인
- 이탈리아
- 기타 유럽
아시아태평양
- 중국
- 일본
- 인도
- 호주
- 한국
- 기타 아시아태평양
- APAC 기타 국가
중동 및 아프리카
- 중동 및 아프리카
  - 사우디아라비아
  - 남아프리카공화국
  - 아랍에미리트(UAE)
  - 기타 중동 및 아프리카
  - 기타 중동 및 아프리카
중남미
- 중남미
  - 브라질
  - 아르헨티나
  - 기타 중남미
  - 기타 중남미

제13장 업계 상황

간질 시장 성장 전략
유기적 성장 전략
무기적 성장 전략

제14장 기업 개요

Abbott Laboratories
Pfizer Inc
Eisai Co Ltd
UCB SA
CombiGene AB
LivaNova Plc
Novartis AG
Medtronic Plc
GSK Plc
H. Lundbeck AS

제15장 부록

LSH 24.04.26

The epilepsy market size is expected to grow from US$ 7.7 billion in 2022 to US$ 10.7 billion by 2030; it is projected to register a CAGR of 4.1% during 2022-2030.

Epilepsy is one of the most common chronic neurological disorders across the world. Associated with an abnormal electrical activity in the brain, this disorder affects over 1 million American women of childbearing age. The rising prevalence of epilepsy and increasing investments in the development of epilepsy therapies are noteworthy factors contributing to the expansion of the epilepsy market size. The administration of anti-epileptic drugs (AEDs) is usually referred to as the first-line treatment for epilepsy. Approximately 80% of the people suffering from epilepsy are from developing countries. In children as well as adults, the treatment of epilepsy is mostly based on the use of drugs (either in monotherapy or combined therapy), while the remaining treatment approaches, such as surgery, neuromodulation, and ketogenic diet, are used at a lesser frequency. However, the recall of products hinders the epilepsy market growth.

Age Group-Based Insights

Based on age group, the epilepsy market is segmented into adults and children. The adults segment held a larger epilepsy market share in 2022. It is further expected to register a higher CAGR in the market during 2022-2030. Epilepsy is more likely to develop in adults as some risk factors for this disease are more common in adults; these include diseases affecting brain function (such as Alzheimer's disease), brain tumors, strokes, and head injuries. According to the Centers for Disease Control and Prevention (CDC), 3 million adults aged 18 or older are living with active epilepsy in the US. Nearly 1 million of these adults are aged 55 or older. As the population ages, even more older people are likely to suffer from epilepsy in the coming years. In 2021, 1.1% of US adults (~2.86 million adults) reported active epilepsy. Thus, medications and treatment strategies often prioritize adult patients, aligning with the demographic prevalence of epilepsy in this age group.

End User-Based Insights

Based on distribution channel, the epilepsy market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest epilepsy market share in 2022. In addition, the retail pharmacies segment is expected to register the highest CAGR in the market during 2022-2030. Retail pharmacy stores sell prescription drugs, over-the-counter drugs, and some fast-moving consumer goods, along with providing related services. Modern retail pharmacy chains are digitized, organized, and tech-enabled, which allows them to track medication inventories and sell 100% reliable goods. In addition, retail pharmacy chains provide value-added services for consumers opting for medical claims or insurance filings. They can also be requested to refurbish previous bills or memos. Moreover, their locations make them accessible for patients to fill their prescriptions and receive counseling from pharmacists.

Centers for Disease Control and Prevention, the World Health Organization, and Neurological Health Charities Canada are among the primary and secondary sources referred to while preparing the epilepsy market report.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Epilepsy Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Epilepsy Market - Key Market Dynamics

5.1 Epilepsy Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Rising Prevalence of Epilepsy
- 5.2.2 Increasing Investments in Development of Epilepsy Therapies
5.3 Market Restraints
- 5.3.1 Recall of Products
5.4 Market Opportunities
- 5.4.1 Surge in Awareness Programs Conducted by Organizations
5.5 Future Trends
- 5.5.1 Gene Therapy as Promising Treatment Approach
5.6 Impact of Drivers and Restraints:

6. Epilepsy Market - Global Market Analysis

6.1 Epilepsy Market Revenue (US$ Million), 2022-2030

7. Epilepsy Market Analysis - by Type

7.1 Overview
7.2 Progressive Myoclonic Epilepsy
- 7.2.1 Overview
- 7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Reflex Epilepsy
- 7.3.1 Overview
- 7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Generalized Epilepsy
- 7.4.1 Overview
- 7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Other
- 7.5.1 Overview
- 7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8. Epilepsy Market Analysis - by Route of Administration

8.1 Overview
8.2 Oral
- 8.2.1 Overview
- 8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
- 8.3.1 Overview
- 8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Others
- 8.4.1 Overview
- 8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9. Epilepsy Market Analysis - by Treatment Type

9.1 Overview
9.2 First Generation Drugs
- 9.2.1 Overview
- 9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Second Generation Drugs
- 9.3.1 Overview
- 9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Third Generation Drugs
- 9.4.1 Overview
- 9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

10. Epilepsy Market Analysis - by Age Group

10.1 Overview
10.2 Adult
- 10.2.1 Overview
- 10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10.3 Children
- 10.3.1 Overview
- 10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11. Epilepsy Market Analysis - by Distribution Channel

11.1 Overview
11.2 Hospital Pharmacies
- 11.2.1 Overview
- 11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.3 Retail Pharmacies
- 11.3.1 Overview
- 11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.4 Others
- 11.4.1 Overview
- 11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12. Epilepsy Market - Geographical Analysis

12.1 North America: Epilepsy Market
- 12.1.1 Overview
- 12.1.2 North America: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  - 12.1.2.1 North America: Epilepsy Market - Revenue and Forecast Analysis - by Type
  - 12.1.2.2 North America: Epilepsy Market - Revenue and Forecast Analysis - by Route of Administration
  - 12.1.2.3 North America: Epilepsy Market - Revenue and Forecast Analysis - by Treatment Type
  - 12.1.2.4 North America: Epilepsy Market - Revenue and Forecast Analysis - by Age Group
  - 12.1.2.5 North America: Epilepsy Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.1.3 North America: Epilepsy Market - Revenue and Forecast Analysis - by Country
  - 12.1.3.1 United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.3.1.1 Overview
    - 12.1.3.1.2 United States: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.3.1.3 United States: Epilepsy Market Breakdown, by Type
    - 12.1.3.1.4 United States: Epilepsy Market Breakdown, by Route of Administration
    - 12.1.3.1.5 United States: Epilepsy Market Breakdown, by Treatment Type
    - 12.1.3.1.6 United States: Epilepsy Market Breakdown, by Age Group
    - 12.1.3.1.7 United States: Epilepsy Market Breakdown, by Distribution Channel
  - 12.1.3.2 Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.3.2.1 Overview
  - 12.1.3.3 Canada: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.3.3.1 Canada: Epilepsy Market Breakdown, by Type
    - 12.1.3.3.2 Canada: Epilepsy Market Breakdown, by Route of Administration
    - 12.1.3.3.3 Canada: Epilepsy Market Breakdown, by Treatment Type
    - 12.1.3.3.4 Canada: Epilepsy Market Breakdown, by Age Group
    - 12.1.3.3.5 Canada: Epilepsy Market Breakdown, by Distribution Channel
  - 12.1.3.4 Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.3.4.1 Overview
  - 12.1.3.5 Mexico: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.3.5.1 Mexico: Epilepsy Market Breakdown, by Type
    - 12.1.3.5.2 Mexico: Epilepsy Market Breakdown, by Route of Administration
    - 12.1.3.5.3 Mexico: Epilepsy Market Breakdown, by Treatment Type
    - 12.1.3.5.4 Mexico: Epilepsy Market Breakdown, by Age Group
    - 12.1.3.5.5 Mexico: Epilepsy Market Breakdown, by Distribution Channel
12.2 Europe: Epilepsy Market
- 12.2.1 Overview
- 12.2.2 Europe: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  - 12.2.2.1 Europe: Epilepsy Market - Revenue and Forecast Analysis - by Type
  - 12.2.2.2 Europe: Epilepsy Market - Revenue and Forecast Analysis - by Route of Administration
  - 12.2.2.3 Europe: Epilepsy Market - Revenue and Forecast Analysis - by Treatment Type
  - 12.2.2.4 Europe: Epilepsy Market - Revenue and Forecast Analysis - by Age Group
  - 12.2.2.5 Europe: Epilepsy Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.2.3 Europe: Epilepsy Market - Revenue and Forecast Analysis - by Country
  - 12.2.3.1 United Kingdom: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.2.3.1.1 Overview
  - 12.2.3.2 United Kingdom: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.2.3.2.1 United Kingdom: Epilepsy Market Breakdown, by Type
    - 12.2.3.2.2 United Kingdom: Epilepsy Market Breakdown, by Route of Administration
    - 12.2.3.2.3 United Kingdom: Epilepsy Market Breakdown, by Treatment Type
    - 12.2.3.2.4 United Kingdom: Epilepsy Market Breakdown, by Age Group
    - 12.2.3.2.5 United Kingdom: Epilepsy Market Breakdown, by Distribution Channel
  - 12.2.3.3 Germany: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.2.3.3.1 Overview
  - 12.2.3.4 Germany: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.2.3.4.1 Germany: Epilepsy Market Breakdown, by Type
    - 12.2.3.4.2 Germany: Epilepsy Market Breakdown, by Route of Administration
    - 12.2.3.4.3 Germany: Epilepsy Market Breakdown, by Treatment Type
    - 12.2.3.4.4 Germany: Epilepsy Market Breakdown, by Age Group
    - 12.2.3.4.5 Germany: Epilepsy Market Breakdown, by Distribution Channel
  - 12.2.3.5 France: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.2.3.5.1 Overview
  - 12.2.3.6 France: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.2.3.6.1 France: Epilepsy Market Breakdown, by Type
    - 12.2.3.6.2 France: Epilepsy Market Breakdown, by Route of Administration
    - 12.2.3.6.3 France: Epilepsy Market Breakdown, by Treatment Type
    - 12.2.3.6.4 France: Epilepsy Market Breakdown, by Age Group
    - 12.2.3.6.5 France: Epilepsy Market Breakdown, by Distribution Channel
  - 12.2.3.7 Spain: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.2.3.7.1 Overview
  - 12.2.3.8 Spain: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.2.3.8.1 Spain: Epilepsy Market Breakdown, by Type
    - 12.2.3.8.2 Spain: Epilepsy Market Breakdown, by Route of Administration
    - 12.2.3.8.3 Spain: Epilepsy Market Breakdown, by Treatment Type
    - 12.2.3.8.4 Spain: Epilepsy Market Breakdown, by Age Group
    - 12.2.3.8.5 Spain: Epilepsy Market Breakdown, by Distribution Channel
  - 12.2.3.9 Italy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.2.3.9.1 Overview
  - 12.2.3.10 Italy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.2.3.10.1 Italy: Epilepsy Market Breakdown, by Type
    - 12.2.3.10.2 Italy: Epilepsy Market Breakdown, by Route of Administration
    - 12.2.3.10.3 Italy: Epilepsy Market Breakdown, by Treatment Type
    - 12.2.3.10.4 Italy: Epilepsy Market Breakdown, by Age Group
    - 12.2.3.10.5 Italy: Epilepsy Market Breakdown, by Distribution Channel
  - 12.2.3.11 Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.2.3.11.1 Overview
  - 12.2.3.12 Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.2.3.12.1 Rest of Europe: Epilepsy Market Breakdown, by Type
    - 12.2.3.12.2 Rest of Europe: Epilepsy Market Breakdown, by Route of Administration
    - 12.2.3.12.3 Rest of Europe: Epilepsy Market Breakdown, by Treatment Type
    - 12.2.3.12.4 Rest of Europe: Epilepsy Market Breakdown, by Age Group
    - 12.2.3.12.5 Rest of Europe: Epilepsy Market Breakdown, by Distribution Channel
12.3 Asia Pacific: Epilepsy Market
- 12.3.1 Overview
- 12.3.2 Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  - 12.3.2.1 Asia Pacific: Epilepsy Market - Revenue and Forecast Analysis - by Type
  - 12.3.2.2 Asia Pacific: Epilepsy Market - Revenue and Forecast Analysis - by Route of Administration
  - 12.3.2.3 Asia Pacific: Epilepsy Market - Revenue and Forecast Analysis - by Treatment Type
  - 12.3.2.4 Asia Pacific: Epilepsy Market - Revenue and Forecast Analysis - by Age Group
  - 12.3.2.5 Asia Pacific: Epilepsy Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.3.3 Asia Pacific: Epilepsy Market - Revenue and Forecast Analysis - by Country
  - 12.3.3.1 China: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.3.3.1.1 Overview
  - 12.3.3.2 China: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.3.3.2.1 China: Epilepsy Market Breakdown, by Type
    - 12.3.3.2.2 China: Epilepsy Market Breakdown, by Route of Administration
    - 12.3.3.2.3 China: Epilepsy Market Breakdown, by Treatment Type
    - 12.3.3.2.4 China: Epilepsy Market Breakdown, by Age Group
    - 12.3.3.2.5 China: Epilepsy Market Breakdown, by Distribution Channel
  - 12.3.3.3 Japan: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.3.3.3.1 Overview
  - 12.3.3.4 Japan: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.3.3.4.1 Japan: Epilepsy Market Breakdown, by Type
    - 12.3.3.4.2 Japan: Epilepsy Market Breakdown, by Route of Administration
    - 12.3.3.4.3 Japan: Epilepsy Market Breakdown, by Treatment Type
    - 12.3.3.4.4 Japan: Epilepsy Market Breakdown, by Age Group
    - 12.3.3.4.5 Japan: Epilepsy Market Breakdown, by Distribution Channel
  - 12.3.3.5 India: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.3.3.5.1 Overview
  - 12.3.3.6 India: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.3.3.6.1 India: Epilepsy Market Breakdown, by Type
    - 12.3.3.6.2 India: Epilepsy Market Breakdown, by Route of Administration
    - 12.3.3.6.3 India: Epilepsy Market Breakdown, by Treatment Type
    - 12.3.3.6.4 India: Epilepsy Market Breakdown, by Age Group
    - 12.3.3.6.5 India: Epilepsy Market Breakdown, by Distribution Channel
  - 12.3.3.7 Australia: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.3.3.7.1 Overview
  - 12.3.3.8 Australia: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.3.3.8.1 Australia: Epilepsy Market Breakdown, by Type
    - 12.3.3.8.2 Australia: Epilepsy Market Breakdown, by Route of Administration
    - 12.3.3.8.3 Australia: Epilepsy Market Breakdown, by Treatment Type
    - 12.3.3.8.4 Australia: Epilepsy Market Breakdown, by Age Group
    - 12.3.3.8.5 Australia: Epilepsy Market Breakdown, by Distribution Channel
  - 12.3.3.9 South Korea: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.3.3.9.1 Overview
  - 12.3.3.10 South Korea: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.3.3.10.1 South Korea: Epilepsy Market Breakdown, by Type
    - 12.3.3.10.2 South Korea: Epilepsy Market Breakdown, by Route of Administration
    - 12.3.3.10.3 South Korea: Epilepsy Market Breakdown, by Treatment Type
    - 12.3.3.10.4 South Korea: Epilepsy Market Breakdown, by Age Group
    - 12.3.3.10.5 South Korea: Epilepsy Market Breakdown, by Distribution Channel
  - 12.3.3.11 Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.3.3.11.1 Overview
  - 12.3.3.12 Rest of APAC: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.3.3.12.1 Rest of APAC: Epilepsy Market Breakdown, by Type
    - 12.3.3.12.2 Rest of APAC: Epilepsy Market Breakdown, by Route of Administration
    - 12.3.3.12.3 Rest of APAC: Epilepsy Market Breakdown, by Treatment Type
    - 12.3.3.12.4 Rest of APAC: Epilepsy Market Breakdown, by Age Group
    - 12.3.3.12.5 Rest of APAC: Epilepsy Market Breakdown, by Distribution Channel
12.4 Middle East & Africa Epilepsy Market
- 12.4.1 Overview
- 12.4.2 Middle East and Africa: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  - 12.4.2.1 Middle East and Africa: Epilepsy Market - Revenue and Forecast Analysis - by Type
  - 12.4.2.2 Middle East and Africa: Epilepsy Market - Revenue and Forecast Analysis - by Route of Administration
  - 12.4.2.3 Middle East and Africa: Epilepsy Market - Revenue and Forecast Analysis - by Treatment Type
  - 12.4.2.4 Middle East and Africa: Epilepsy Market - Revenue and Forecast Analysis - by Age Group
  - 12.4.2.5 Middle East and Africa: Epilepsy Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.4.3 Middle East and Africa: Epilepsy Market - Revenue and Forecast Analysis - by Country
  - 12.4.3.1 Saudi Arabia: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.4.3.1.1 Overview
  - 12.4.3.2 Saudi Arabia: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.4.3.2.1 Saudi Arabia: Epilepsy Market Breakdown, by Type
    - 12.4.3.2.2 Saudi Arabia: Epilepsy Market Breakdown, by Route of Administration
    - 12.4.3.2.3 Saudi Arabia: Epilepsy Market Breakdown, by Treatment Type
    - 12.4.3.2.4 Saudi Arabia: Epilepsy Market Breakdown, by Age Group
    - 12.4.3.2.5 Saudi Arabia: Epilepsy Market Breakdown, by Distribution Channel
  - 12.4.3.3 South Africa: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.4.3.3.1 Overview
  - 12.4.3.4 South Africa: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.4.3.4.1 South Africa: Epilepsy Market Breakdown, by Type
    - 12.4.3.4.2 South Africa: Epilepsy Market Breakdown, by Route of Administration
    - 12.4.3.4.3 South Africa: Epilepsy Market Breakdown, by Treatment Type
    - 12.4.3.4.4 South Africa: Epilepsy Market Breakdown, by Age Group
    - 12.4.3.4.5 South Africa: Epilepsy Market Breakdown, by Distribution Channel
  - 12.4.3.5 United Arab Emirates: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.4.3.5.1 Overview
  - 12.4.3.6 United Arab Emirates: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.4.3.6.1 United Arab Emirates: Epilepsy Market Breakdown, by Type
    - 12.4.3.6.2 United Arab Emirates: Epilepsy Market Breakdown, by Route of Administration
    - 12.4.3.6.3 United Arab Emirates: Epilepsy Market Breakdown, by Treatment Type
    - 12.4.3.6.4 United Arab Emirates: Epilepsy Market Breakdown, by Age Group
    - 12.4.3.6.5 United Arab Emirates: Epilepsy Market Breakdown, by Distribution Channel
  - 12.4.3.7 Rest of Middle East & Africa: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.4.3.7.1 Overview
  - 12.4.3.8 Rest of Middle East and Africa: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.4.3.8.1 Rest of Middle East and Africa: Epilepsy Market Breakdown, by Type
    - 12.4.3.8.2 Rest of Middle East and Africa: Epilepsy Market Breakdown, by Route of Administration
    - 12.4.3.8.3 Rest of Middle East and Africa: Epilepsy Market Breakdown, by Treatment Type
    - 12.4.3.8.4 Rest of Middle East and Africa: Epilepsy Market Breakdown, by Age Group
    - 12.4.3.8.5 Rest of Middle East and Africa: Epilepsy Market Breakdown, by Distribution Channel
12.5 South & Central America: Epilepsy Market
- 12.5.1 Overview
- 12.5.2 South and Central America: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  - 12.5.2.1 South and Central America: Epilepsy Market - Revenue and Forecast Analysis - by Type
  - 12.5.2.2 South and Central America: Epilepsy Market - Revenue and Forecast Analysis - by Route of Administration
  - 12.5.2.3 South and Central America: Epilepsy Market - Revenue and Forecast Analysis - by Treatment Type
  - 12.5.2.4 South and Central America: Epilepsy Market - Revenue and Forecast Analysis - by Age Group
  - 12.5.2.5 South and Central America: Epilepsy Market - Revenue and Forecast Analysis - by Distribution Channel
- 12.5.3 South and Central America: Epilepsy Market - Revenue and Forecast Analysis - by Country
  - 12.5.3.1 Brazil: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.5.3.1.1 Overview
  - 12.5.3.2 Brazil: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.5.3.2.1 Brazil: Epilepsy Market Breakdown, by Type
    - 12.5.3.2.2 Brazil: Epilepsy Market Breakdown, by Route of Administration
    - 12.5.3.2.3 Brazil: Epilepsy Market Breakdown, by Treatment Type
    - 12.5.3.2.4 Brazil: Epilepsy Market Breakdown, by Age Group
    - 12.5.3.2.5 Brazil: Epilepsy Market Breakdown, by Distribution Channel
  - 12.5.3.3 Argentina: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.5.3.3.1 Overview
  - 12.5.3.4 Argentina: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.5.3.4.1 Argentina: Epilepsy Market Breakdown, by Type
    - 12.5.3.4.2 Argentina: Epilepsy Market Breakdown, by Route of Administration
    - 12.5.3.4.3 Argentina: Epilepsy Market Breakdown, by Treatment Type
    - 12.5.3.4.4 Argentina: Epilepsy Market Breakdown, by Age Group
    - 12.5.3.4.5 Argentina: Epilepsy Market Breakdown, by Distribution Channel
  - 12.5.3.5 Rest of South & Central America: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.5.3.5.1 Overview
  - 12.5.3.6 Rest of South and Central America: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.5.3.6.1 Rest of South and Central America: Epilepsy Market Breakdown, by Type
    - 12.5.3.6.2 Rest of South and Central America: Epilepsy Market Breakdown, by Route of Administration
    - 12.5.3.6.3 Rest of South and Central America: Epilepsy Market Breakdown, by Treatment Type
    - 12.5.3.6.4 Rest of South and Central America: Epilepsy Market Breakdown, by Age Group
    - 12.5.3.6.5 Rest of South and Central America: Epilepsy Market Breakdown, by Distribution Channel

13. Industry Landscape

13.1 Overview
13.2 Growth Strategies in Epilepsy Market
13.3 Organic Growth Strategies
- 13.3.1 Overview
13.4 Inorganic Growth Strategies
- 13.4.1 Overview

14. Company Profiles

14.1 Abbott Laboratories
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Pfizer Inc
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Eisai Co Ltd
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 UCB SA
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 CombiGene AB
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 LivaNova Plc
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Novartis AG
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Medtronic Plc
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 GSK Plc
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 H. Lundbeck AS
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments

15. Appendix

15.1 About The Insight Partners

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다.

US $ 4,450

￦ 6,368,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,450

￦ 9,231,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,450

￦ 12,093,000

※ 부가세 별도

간질 - 시장 규모 및 예측, 세계 및 지역별 점유율, 동향, 성장 기회 분석 보고서 : 유형별, 투여 경로별, 치료 유형별, 연령대별, 유통 채널별, 지역별

Epilepsy Market Size and Forecasts, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Route of Administration, Treatment Type, Age Group, Distribution Channel, and Geography

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 간질 시장 구도

제5장 간질 시장 : 주요 시장 역학

제6장 간질 시장 : 세계 시장 분석

제7장 간질 시장 분석 : 유형별

제8장 간질 시장 분석 : 투여 경로별

제9장 간질 시장 분석 : 치료 유형별

제10장 간질 시장 분석 : 연령층별

제11장 간질 시장 분석 : 유통 채널별

제12장 간질 시장 : 지역별 분석